Published in Women's Health Weekly, February 21st, 2008
Using proprietary tissue processing technologies, EPI is developing a quantitative assay for HER2 (human epidermal growth factor receptor 2) in breast cancer. EPI's Liquid Tissue(R) reagents and Director(TM) laser microdissection slides are used to extract proteins from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly